Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Purity: ≥98%
Pristinamycin IA (also known as Mikamycin B; Mikamycin IA), a naturally occuring and biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a novel and potent cholecystokinetic agent which acts as a cholecystokinin receptor agonist.
ln Vitro |
Pristinamycin IA (100 μM, 0–4 h) suppresses the disruption of [3H]vinblastine in Caco-2 cells [1]. Pristinamycin IA (4.614 μM) stimulates the ribosome-supporting ribose regulatory factor (LRR), and Pristinamycin IA (100 μM) and [3H]vinblastine rescue in Caco-2 cell monolayers [2].
|
---|---|
References |
[1]. Phung-Ba V et al. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol. 1995 Jan 16;288(2):187-92.
[2]. Xia Cai, et al. Attenuator LRR - a regulatory tool for modulating gene expression in Gram-positive bacteria. Microb Biotechnol. 2021 Nov;14(6):2538-2551. |
Molecular Formula |
C45H54N8O10
|
---|---|
Molecular Weight |
866.957860000001
|
CAS # |
3131-03-1
|
Related CAS # |
Pristinamycin;270076-60-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(C(N(C(C(CCC1)N1C(C(NC2=O)CC)=O)=O)C)CC3=CC=C(N(C)C)C=C3)N(CCC4=O)C(C4)C(NC(C5=CC=CC=C5)C(OC(C2NC(C(N=CC=C6)=C6O)=O)C)=O)=O
|
Synonyms |
Mikamycin B; Mikamycin IA
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~38.44 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1535 mL | 5.7673 mL | 11.5346 mL | |
5 mM | 0.2307 mL | 1.1535 mL | 2.3069 mL | |
10 mM | 0.1153 mL | 0.5767 mL | 1.1535 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Attenuator LRR is of good regulatory performance.A. Regulation mechanism of the attenuator LRR. LRR forms a terminator structure under no antibiotic condition, which inhibits the transcription of lacZ mRNA and generates short transcripts. In the presence of antibiotics, ribosome stalling induced by antibiotics results in the formation of an anti‐terminator structure of LRR. Consequently, the expression of lacZ is increased obviously.B. Antibiotics induce LacZ expression. NA, no antibiotics; Tet, tetracycline (1 μg ml−1, 2.25 μM); Vgm, virgimycin M (1 μg ml−1, 1.903 μM); Rap, rapamycin (8 μg ml−1, 8.751 μM); Lin, lincomycin (4 μg ml−1, 9.839 μM); Pnm, pristinamycin IA (4 μg ml−1, 4.614 μM); Cam, chloramphenicol (1 μg ml−1, 3.095 μM); Lnz, linezolid (0.2 μg ml−1, 0.593 μM); Tel, telithromycin (2.5 μg ml−1, 3.079 μM); Kan, kanamycin (2 μg ml−1, 3.433 μM); Rtm, retapamulin (0.5 μg ml−1, 0.965 μM); Van, vancomycin (1.5 μg ml−1, 1.01 μM). The numbers above the columns are the fold change induced by antibiotics. The fold change was calculated by dividing the Miller units under antibiotic conditions by the Miller units under no antibiotic condition.[2].Attenuator LRR - a regulatory tool for modulating gene expression in Gram-positive bacteria. Microb Biotechnol. 2021 Nov;14(6):2538-2551. td> |